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The Honorable John E. Baldacci
The Honorable John F. Tierney
House of Representatives
Proponents and opponents of modern agricultural biotechnology hold
passionate views about the benefits and risks of using this technology to
produce genetically modified (GM) food.1 Proponents cite enhanced crop
yields, more environmentally friendly food production, and more
nutritious foods as reasons to move forward. Opponents of biotechnology
argue that not enough is known about the safety of these foods and that
they should be more rigorously controlled.
While confidence in the safety of GM foods is essential to their commercial
success, governments and consumers from different parts of the world
have taken very different positions on their safety and regulation. Some
consumers in Western Europe have shown their opposition to this
technology by destroying GM food crops, and European regulatory entities
have not approved any new GM foods in the past several years. In the
United States, consumers and regulatory agencies, such as the Food and
Drug Administration (FDA), generally support GM foods, with a number of
these foods having been made available for sale in recent years. However,
the debate on the safety of these foods is ongoing and may intensify in the
future as genetic modifications to foods become increasingly complex.
To ensure public confidence in GM foods, the U.S. biotechnology industry
recognized in the early 1990s the need for oversight by FDA, which has
primary responsibility for the safety of most of the nation’s food supply.2 In
response, FDA published guidelines in 1992 to ensure that companies
developing GM foods worked with the agency in assessing the safety of
these foods. As part of the process, companies test new GM foods to
                                                                                                                                   
1 Modern agricultural biotechnology is a collection of scientific techniques, such as genetic
engineering, used to modify plants, animals, or microorganisms by introducing desired
traits in them, including characteristics from unrelated species. For example, traits may be
introduced to facilitate pest management and improve yield or nutritional value. In this
report, we will refer to food derived from genetically modified plants as GM foods.
2 The U.S. Department of Agriculture’s (USDA) Food Safety and Inspection Service is
responsible for ensuring the safety of meat, poultry, and egg products. FDA is responsible
for all other foods, including seafood.
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assess their safety, including their potential health risks, and submit test
data to FDA for evaluation.3 As of April 2002, FDA has evaluated 50 GM
foods, many of which have subsequently been placed on the market.
Currently, submission of information to FDA is voluntary, but FDA
published a proposed rule in January 2001 that would make this
submission mandatory.
In light of the continued debate about GM foods, you asked us to (1)
identify the types of potential human health risks associated with GM
foods and experts’ views regarding the adequacy of tests used to evaluate
these risks, (2) describe FDA’s controls for ensuring that companies
submit test data it requests and identify experts’ views of the agency’s
overall evaluations of these foods, (3) describe potential changes in future
GM foods and any associated changes in tests to evaluate them, and (4)
identify experts’ views on the necessity and feasibility of monitoring the
long-term health risks of these foods.
To conduct this work, we reviewed scientific and technical studies and
other literature and spoke with experts in government, academia, private
industry, and consumer groups. We selected these experts in consultation
with officials from the National Academy of Sciences. As agreed with your
offices, we did not assess the potential environmental risks associated
with GM food production. In addition, since there have been no GM
animals evaluated for commercialization, we did not assess their potential
environmental or human health risks. Also, we did not independently
evaluate FDA’s controls for ensuring it receives safety data. Further details
of the scope and methodology of our review are discussed in appendix I.
GM foods pose the same types of inherent risks to human health as
conventional foods: they can contain allergens, toxins, and compounds
known as antinutrients, which inhibit the absorption of nutrients. Before
marketing a GM food, company scientists evaluate these risks—even
though they are not routinely evaluated in conventional foods—to
determine if the foods pose any heightened risks. While some GM foods
have contained allergens, toxins, and antinutrients, the levels have been
comparable to those foods’ conventional counterparts. In evaluating GM
foods, scientists perform a regimen of tests. Biotechnology experts whom
                                                                                                                                   
3 In general, risk assessment involves several steps, including identifying the hazard (type
of risk) and assessing the level of exposure to the hazard.
Results in Brief
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we contacted agree that this regimen of tests is adequate in assessing the
safety of GM foods. While some consumer groups, as well as some
scientists from the European Union, have questioned the ethical or
cultural appropriateness of genetically modifying foods, experts whom we
contacted from these organizations also believe the tests are adequate for
assessing the safety of these foods.
While FDA reports that its evaluation process includes the necessary
controls for ensuring it obtains the safety data needed to evaluate GM
foods, some biotechnology experts state that aspects of its evaluation
process could be enhanced. FDA’s controls include (1) communicating
clearly—through the agency’s 1992 policy statement and subsequent
guidance—what safety data are necessary for its evaluations of GM food
safety; (2) having teams of FDA experts in diverse disciplines evaluate
company submissions for GM foods and request additional safety data, if
necessary; and (3) tailoring the level of evaluation to match the degree of
each submission’s novelty, thereby assuring that staff have time to obtain
necessary safety data. Nonetheless, FDA’s overall evaluation process
could be enhanced, according to some experts, by randomly verifying the
test data that companies provide and by increasing the transparency of the
evaluation process—including communicating more clearly the scientific
rationale for the agency’s final decision on a GM food safety assessment.
In the future, scientists generally expect that genetic modifications will
increasingly change the composition of GM foods to enhance their
nutritional value. For example, one company has modified a type of rice to
contain beta-carotene. In countries where rice is a dietary staple, this rice
may reduce the incidence of blindness caused by vitamin-A deficiency.
Current tests have been adequate for evaluating the few GM foods with
relatively simple compositional changes that FDA has reviewed so far.
New testing technologies are being developed to evaluate the increasingly
complex compositional changes expected. Some scientists view these new
technologies as a potentially useful supplement for existing tests, while
others believe that the technologies will offer a more comprehensive way
of assessing the safety of all changes in GM foods.
Monitoring the long-term health risks of GM foods is generally neither
necessary nor feasible, according to scientists and regulatory officials we
contacted. In their view, such monitoring is unnecessary because there is
no scientific evidence, or even a hypothesis, suggesting that long-term
harm (such as increased cancer rates) results from these foods.
Furthermore, there is consensus among these scientists and regulatory
officials that technical challenges make long-term monitoring infeasible.
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Experts cite, for example, the technical inability to track the health effects
of GM foods separately from those of their conventional counterparts. A
recent report by food and health organizations affiliated with the United
Nations also expresses skepticism about the feasibility of identifying long-
term health effects from GM foods.
This report contains recommendations to the Deputy Commissioner of
Food and Drugs for enhancing the effectiveness of FDA’s safety
evaluations of GM foods. The recommendations concern the need to
randomly verify test data and increase the transparency of the agency’s
safety evaluations of these foods. In commenting on a draft of this report,
FDA agreed with our recommendations and stated that the
recommendations would increase the transparency of, and public
confidence in, FDA’s evaluations of GM foods. FDA also provided
technical comments which we incorporated as appropriate.
Modern agricultural biotechnology refers to various scientific techniques,
most notably genetic engineering, used to modify plants, animals, or
microorganisms by introducing into their genetic makeup genes for
specific desired traits, including genes from unrelated species. For
centuries people have crossbred related plants or animal species to
develop useful new varieties or hybrids with desirable traits, such as better
taste or increased productivity. Traditional crossbreeding, however, can
be very time-consuming because it may require breeding several
generations to obtain a desired trait and breed out numerous unwanted
characteristics. Genetic engineering techniques allow for faster
development of new crop or livestock varieties, since the genes for a given
trait can be readily introduced into a plant or animal species to produce a
new variety incorporating that specific trait. Additionally, genetic
engineering increases the range of traits available for developing new
varieties by allowing genes from totally unrelated species to be
incorporated into a particular plant or animal variety.
In the 1970s, scientists learned how to extract a specific gene from a DNA
strand and insert this gene into a different organism where it would
continue to make the same protein that it did in its original organism.
Scientists have applied this technology to bacteria, plants, and animals.
For example, as shown in figure 1, scientists produced pest-resistant
plants by identifying a gene responsible for pest resistance in an organism,
isolating and copying the gene, and then inserting it into the target plant’s
DNA. The plant was then tested to determine that the transferred trait
Background
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(transgene) was inherited in subsequent generations and that the
“transgenic” plant grew and functioned as well as the conventional variety.
Figure 1: Use of Biotechnology to Create a Pest-Resistant Plant
Biotechnology offers a variety of potential benefits and risks. It has
enhanced food production by making plants less vulnerable to drought,
frost, insects, and viruses and by enabling plants to compete more
effectively against weeds for soil nutrients. In a few cases, it has also
improved the quality and nutrition of foods by altering their composition.
Table 1 summarizes the GM foods evaluated by FDA.
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Table 1: GM Foods for Human Consumption Evaluated by FDA
Modified Attribute
Insect
Resistance
Viral
Resistance
Herbicide
Tolerance
Modified
Oil
Plant
Reproductive
Sterility
Delayed
Ripening/
Softening
GM Plant Product—# of Plant
Varieties
Corn—8
Tomato—1
Potato—4
Cotton—2
Squash—2
Papaya—1
Potato—2
Corn—9
Rice—1
Canola—8
Sugar Beet—2
Flax—1
Cottona—4
Radish—1
Soybean—2
Soybean—1
Canola—1
Corn—3
Canola—3
Radish—1
Cantaloupe—1
Tomato—4
Totalb 15 5 28 2 7 5
aCotton seed has been used as a protein source in candy.
bFifty products have been evaluated, as of April 2002. The total number of modified attributes is 62
because several products were modified with multiple attributes.
Source: GAO analysis of FDA data.
Table 1 shows that the majority of modifications have been aimed at
increasing crop yields for farmers by engineering a food plant to tolerate
herbicides or attacks from pests such as insects and viruses (48 out of 62
modifications). Further, only two food plants have been altered to produce
modified oil: the soybean and canola plants. According to industry
officials, the modified soybean produces healthier oil. They also stated
that the canola plant was modified to have a domestic source for laurate
cooking oil.4 Because soybean oil is the most commonly consumed plant
oil worldwide, scientists say that the new oil could significantly improve
the health of millions of people.
For three key crops grown in the United States—corn, soybeans, and
cotton—a large number of farmers have chosen to plant GM varieties. In
2001, GM varieties accounted for about 26 percent of the corn, 68 percent
of the soybeans, and 69 percent of the cotton planted in the United States.
These crops are the source of various ingredients used extensively in
many processed foods, such as corn syrup, soybean oil, and cottonseed
oil, and they are also major U.S. commodity exports. The United States
accounts for about three-quarters of GM food crops planted globally.
                                                                                                                                   
4 Laurate canola oil is a form of canola oil that contains lauric acid, a fatty acid found in
tropical oils. As a result, laurate canola oil can substitute for palm kernel oil which is an
imported tropical oil.
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However, the use of biotechnology has also raised concerns about its
potential risks to the environment and people. For example, some people
fear that common plant pests could develop resistance to the introduced
pesticides in GM crops that were supposed to combat them. Further, some
fear that crops modified to be tolerant to herbicides could foster the
evolution of “super weeds.” Finally, some fear that scientists might
unknowingly create or enhance a food allergen or toxin. Therefore, as
biotechnology was being developed, U.S. scientists, regulators, and
policymakers generally agreed that GM plants should be evaluated
carefully before being put into widespread use. As a result, the United
States published a Coordinated Framework for Regulation of
Biotechnology in 1986. This framework outlined the regulatory approach
for reviewing GM plants, including relevant laws, regulations, and
definitions of GM organisms.
Responsibility for implementing the coordinated framework fell primarily
to three agencies: USDA, the Environmental Protection Agency (EPA), and
FDA. Within USDA, the Animal and Plant Health Inspection Service
(APHIS) bears the main responsibility for assessing the environmental
safety of GM crops. The primary focus of APHIS’ review is to determine
whether or not a plant produced through biotechnology has the potential
to harm natural habitats or agriculture. Developers can petition APHIS to
exempt a GM plant from regulation once sufficient and appropriate data
have been collected regarding the potential environmental impact of a GM
plant.
To safeguard the environment and human health, EPA is responsible for
regulating genetic modifications in plants that protect them from insects,
bacteria, and viruses. These protectants are subject to the agency’s
regulations on the sale, distribution, and use of pesticides. EPA must
review and grant a permit for field-testing plants with such protectants on
more than 10 acres of land. Prior to commercialization of a GM plant with
such a protectant, EPA reviews the application for approval of the
protectant, solicits public comments, and may seek the counsel of external
scientific experts.
FDA has primary authority for the safety of most of the food supply. The
Federal Food, Drug, and Cosmetic Act establishes the standard for food
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safety as food being in an unadulterated condition.5 FDA established its
basic policy regarding the review of GM foods in its 1992 Policy on Foods
Derived from New Plant Varieties. According to this policy, FDA relies on
companies developing GM foods to voluntarily notify the agency before
marketing the foods.6 Notification leads to a two-part consultation process
between the agency and the company that initially involves discussions of
relevant safety issues and subsequently the company’s submission of a
safety assessment report containing test data on the food in question. At
the end of the consultation, FDA evaluates the data and may send a letter
to the company stating that the agency has no further questions, indicating
in effect that it sees no reason to prevent the company from marketing the
GM food. In 1997, FDA supplemented its 1992 Policy with the current
Guidance on Consultation Procedures, clarifying procedures for the
initial and final consultations.
In January 2001, FDA issued a proposed rule in the Federal Register that
provides further information on these procedures and, more importantly,
would require pre-market notification by companies. Among the reasons
that FDA cited for this change are concerns expressed by consumers and
public interest groups about the limited transparency and voluntary nature
of the current process. FDA also pointed to the growing power of
biotechnology to create potentially more complex safety issues that could
require more stringent regulatory evaluations. FDA, tentatively, expects to
finalize this rule as early as fiscal year 2003.
                                                                                                                                   
5 21 U.S.C. § 342. A food is deemed adulterated if, among other things, it contains an added
poisonous or deleterious substance that may render the food injurious to health or if it
contains an unapproved food additive.
6 FDA has not routinely evaluated the safety of foods derived from new plant varieties that
were produced by traditional breeding. FDA has generally not evaluated these foods
because plant breeders have longstanding established and reliable practices  for ensuring
food safety.
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All foods, including those from GM plants, pose the same types of inherent
risks to human health: they can cause allergic or toxic reactions, or they
can block the absorption of nutrients. Although some foods from GM
plants have contained allergens, toxins, and antinutrients, scientists agree
that the levels of these compounds have been comparable to those found
in the foods’ conventional counterparts. To reach such a finding, each GM
food is evaluated using a regimen of tests. This regimen begins with tests
on the source of the gene being transferred, proceeds to tests examining
the similarity of the GM food to conventional varieties with known
allergens, toxins, and antinutrients, and may include tests on the safety of
the modified protein from the GM food in simulated digestive fluids. At
every phase, test results are compared to the risk levels found in the food’s
conventional counterpart. If the risk levels are within the same range as
those for the conventional food, the GM food is considered as safe as its
conventional counterpart. Despite the limitations of individual tests,
several experts agree that this regimen of tests has been adequate for
ensuring the safety of GM foods.
According to reports from the Organization for Economic Cooperation and
Development, the Codex Alimentarius,7 and FDA, foods from GM plants
pose three types of risk to human health: they can potentially contain
allergens, toxins, or antinutrients. These risks are not unique to GM foods.
People have consumed foods containing allergens, toxins, and
antinutrients throughout human history. The small percentage of the
population with food allergies (1-2 percent of adults and 6-8 percent of
children) tries to prevent allergic reactions by avoiding offending foods.
Additionally, people commonly consume toxic substances in foods, but
they usually do so at levels that are considered safe. People also frequently
consume foods containing antinutrients, such as certain proteins that
inhibit the digestion of nutrients in the intestinal tract, but common food
preparation techniques, such as cooking, break down the antinutrients.
Moreover, consumption of a varied diet, in which a person is exposed to
multiple nutrient sources, mitigates the risk of malnutrition from
antinutrients, according to FDA officials and various academicians.
                                                                                                                                   
7 Codex Alimentarius is the joint food standards program for the United Nations’ Food and
Agriculture Organization and the World Health Organization that was established in 1962.
Its objectives are to help protect the health of consumers and facilitate trade through the
establishment of international food standards, codes of practice, and other guidelines.
GM Foods Share the
Same Types of Health
Risks as Conventional
Foods and Are
Evaluated by Tests
That Appear Adequate
All Foods Share the Same
Three Risks, Which Are
Evaluated in GM Foods
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Because conventional foods contain allergens, toxins, and antinutrients,
scientists recognize that food cannot be guaranteed to pose zero risk. The
primary concern with the genetic modification of food with respect to
human health, state industry officials, is the potential for unintentional
introduction of a new allergen, an enhanced toxin, or an enhanced
antinutrient in an otherwise safe food. For this reason, developers
evaluate GM foods to determine if they are as safe as their conventional
counterparts.
An allergic reaction is an abnormal response of the body’s immune system
to an otherwise safe food. Some reactions are life threatening, such as
anaphylactic shock.8 To avoid introducing or enhancing an allergen in an
otherwise safe food, the biotech food industry evaluates GM foods to
determine whether they are “as safe as” their natural counterparts. For
example, in 1996 FDA reviewed the safety assessment for a GM soybean
plant that can produce healthier soybean oil. As part of a standard safety
assessment, the GM soybean was evaluated to see if it was as safe as a
conventional soybean. Although soybeans are a common food allergen and
the GM soybean remained allergenic, the results showed no significant
difference between its allergenicity and that of conventional soybeans.
Specifically, serums (blood) from individuals allergic to the GM soybean
showed the same reactions to conventional soybeans.
A toxic reaction in humans is a response to a poisonous substance. Unlike
allergic reactions, all humans are subject to toxic reactions. Scientists
involved in developing a GM food aim to ensure that the level of toxicity in
the food does not exceed the level in the food’s conventional counterpart.
If a GM food has toxic components outside the natural range of its
conventional counterpart, the GM food is not acceptable.
To date, GM foods have proven to be no different from their conventional
counterparts with respect to toxicity. In fact, in some cases there is more
confidence in the safety of GM foods because naturally occurring toxins
that are disregarded in conventional foods are measured in the pre-market
safety assessments of GM foods. For example, a naturally occurring toxin
in tomatoes, known as tomatine, was largely ignored until a company in
the early 1990s developed a GM tomato. FDA and the company considered
it important to measure potential changes in tomatine. Through an
analysis of conventional tomatoes, they showed that the levels of
                                                                                                                                   
8 Anaphylactic shock is a severe allergic reaction that can lead to death.
Allergic Reactions
Toxic Reactions
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tomatine, as well as other similar toxins in the GM tomato, were within the
range of its conventional counterpart.
Antinutrients are naturally occurring compounds that interfere with
absorption of important nutrients in digestion. If a GM food contains
antinutrients, scientists measure the levels and compare them to the range
of levels in the food’s conventional counterpart. If the levels are similar,
scientists usually conclude that the GM food is as safe as its conventional
counterpart. For example, in 1995 a company submitted to FDA a safety
assessment for GM canola. The genetic modification altered the fatty acid
composition of canola oil. To minimize the possibility that an unintended
antinutrient effect had rendered the oil unsafe, the company compared the
antinutrient composition of its product to that of conventional canola. The
company found that the level of antinutrients in its canola did not exceed
the levels in conventional canola.
To ensure that GM foods do not have decreased nutritional value,
scientists also measure the nutrient composition, or “nutrition profile,” of
these foods. The nutrient profile depends on the food, but it often includes
amino acids, oils, fatty acids, and vitamins. In the example previously
discussed, the company also presented data on the nutrient profile of the
GM canola and concluded that the significant nutrients were within the
range of those in conventional canola.
Companies that may wish to submit new GM foods for FDA evaluation
perform a regimen of tests to obtain safety data on these foods. FDA’s
1992 policy on safety assessments of GM foods describes the data the
agency recommends it receive to evaluate these foods. Figure 2 provides
an example of the regimen of tests. This regimen usually includes an
analysis of
• the source of the transferred genetic material, specifically whether the
source of the transferred gene has a history of causing allergic or toxic
reactions or containing antinutrients;
• the degree of similarity between the amino acid9 sequences in the newly
introduced proteins of the GM food and the amino acid sequences in
known allergens, toxins, and antinutrients;
                                                                                                                                   
9 Amino acids are the “building blocks” of the proteins in the body. Besides building cells
and repairing tissue, the proteins form antibodies to combat invading bacteria and viruses,
build DNA and RNA, and carry oxygen throughout the body.
Antinutrient Effects
Companies Use a Regimen
of Tests to Ensure GM
Food Safety
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• data on in vitro digestibility (i.e., how readily the proteins break down in
simulated digestive fluids)
• the comparative severity of individual allergic reactions to the GM product
and its conventional counterpart as measured through blood (serum)
screening—when the conventional counterpart is known to elicit allergic
reactions or allergenicity concerns remain; and
• data on any changes in nutrient substances, such as vitamins, proteins,
fats, fiber, starches, sugars, or minerals due to genetic modification.
Occasionally, the regimen of tests also includes animal studies for toxicity.
As shown in figure 2, the tests provide evidence at key decision points to
direct which tests are subsequently performed. Tests on the source of the
newly expressed protein, amino acid sequence similarity, and digestibility
are typical for both allergenicity and toxicity assessments, while serum
screening is used only for allergenicity assessment. Also, while the
complete regimen is not necessary for every GM food safety assessment,
companies often perform extra tests in the regimen to corroborate the
results of previous tests.
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Figure 2: Example of the Regimen of Tests Used for Safety Assessments of GM
Foods
Source: GAO’s analysis of FDA documents.
Notes:
Figure 2 represents typical tests undertaken by a company in the safety assessment of a GM food.
The figure is not meant to be a comprehensive illustration that is used in every safety assessment.
Antinutrients are tested as a subset of toxicity. In addition, they are often measured with a simple
nutrition/composition profile.
If a company transfers genetic material from an allergenic source and undertakes serum screening
tests, it does not have to go though serum screening again if in vitro digestibility tests uncover a
similarity to an allergen.  At such a point, it would be assessed by amino acid sequence similarity and
in vitro digestibility tests for potential toxicity.
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If a company reaches the “Stop (or consult)” decision point, then there are food safety concerns about
allergenicity or toxicity issues. At this point, FDA’s 1992 policy statement says the company should
consult with FDA. However, this usually means the company will discontinue development of the GM
product because of allergenicity or toxicity concerns. A company may consult with FDA if there were
changes in the nutrition/composition profile that were intended.
Animal studies are occasionally conducted as an extra test for potential toxicity.
Using allergenicity as an example, if a company transfers a gene from a
source that is not an allergen, the company evaluates the amino acid
sequence of the GM protein. If the GM protein has an amino acid sequence
similar to that of known allergens, the company initiates further, more
specific allergenicity testing. The company would undertake in vitro
digestibility tests to see if the GM protein was broken down in simulated
digestive fluids. If there were any concerns about the speed with which the
GM protein was broken down, the company would use serum-screening
tests to support or refute the results of the digestibility tests when serums
are available. If the serum screening yields results showing that the GM
protein does not react with antibodies in serum, then the company
concludes the GM protein does not raise allergenicity concerns. The
results from this regimen of tests provide the weight of evidence necessary
to determine the safety of a GM food.
Examining the source of the transferred genetic material is the starting
point in the regimen of tests for safety assessments. According to a
scientist from a biotechnology company, two principles of allergenicity
assessment underlying the regimen of tests contribute to adequate safety
assessments: scientists (1) avoid transferring known allergenic proteins
and (2) assume all genes transferred from allergenic sources create new
food allergies until proven otherwise. If the source contains a common
allergen or toxin, industry scientists must prove that the allergenic or toxic
components have not been transferred. However, as a practical matter,
biotechnology companies repeatedly state that if the conventional food is
considered a major food allergen,10 they will not transfer genes from that
source. Accordingly, experts from FDA and the biotechnology industry
agree that the probability of introducing a new allergen, enhancing a toxin,
or enhancing an antinutrient is very small.
The next step involves a comparison between the amino acid sequences of
the transferred proteins of the GM food plant and those of known
allergens, toxins, or antinutrients. If scientists detect an amino acid
                                                                                                                                   
10 Major food allergens are dairy milk, eggs, fish, peanuts, shellfish, soybeans, tree nuts, and
wheat.
Source of the Transferred
Genetic Material
Amino Acid Sequence
Similarity
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sequence in a GM food identical or similar to one in an allergen, toxin, or
antinutrient, then there is a likelihood that the GM food poses a health
risk. Overall, sequence similarity tests are very useful in eliminating areas
of concern and revealing areas for further evaluation.
In vitro digestibility tests are a primary component of all GM food safety
assessments. These tests analyze the breakdown of a GM protein in
simulated human digestive or gastric fluids. The quick breakdown of a GM
protein in these fluids indicates a very high likelihood that the protein is
not allergenic or toxic. Safe dietary proteins are almost always rapidly
digested, while allergens and toxins are not.
If a gene raises allergenicity concerns, a company can include serum
screening tests in its safety assessment of a GM food. Serum screening is
used only for allergenicity assessment. Serum screening involves
evaluating the reactivity of antibodies in the blood of individuals with
known allergies to the plant that was the source of the transferred gene.
Antibody reactions suggest the presence of an allergenic protein. Serum
screening tests are valuable because they can expose allergens whose
presence was only suggested in amino acid sequence similarity tests.11
Since there are neither abundant, appropriate stored serums nor many
suitable human test subjects, these tests cannot always be used.
Scientists also create a nutritional and compositional12 profile of the GM
food to assess whether any unexpected changes in nutrients, vitamins,
proteins, fibers, starches, sugars, minerals, or fats have occurred as a
result of the genetic modification. While changes in these substances do
not pose a risk of allergenicity, toxicity, or antinutrient effects to human
health, creating a nutritional and compositional profile further ensures
that the GM food is comparable to its conventional counterpart.
                                                                                                                                   
11 Clinical tests to corroborate the results of serum screening include skin prick tests and
double-blind placebo-control food challenges. Skin prick tests involve scratching the skin
of individuals with food allergies to determine if the new GM product elicits allergic skin
reactions. Double-blind placebo-control food challenges aim to eliminate possible
psychosomatic reactions of allergic individuals by giving them either a test product or a
control product.
12 “Compositional” refers to the concentration of nutrients and other key substances in a
plant, since the concentration of nutrients—not just the presence—is important in
assessing unexpected changes.
Digestibility Tests
Serum Screening
Nutritional and Compositional
Profile
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Biotechnology companies occasionally use animal studies to confirm the
results of prior toxicity tests. For the most part, these studies have
involved feeding extraordinarily high doses of the modified protein from a
GM food to mice. The doses of the modified protein are often hundreds to
thousands of times higher than the likely dose from human diets.
Scientists perform these studies to determine if there are any toxic
concerns from the GM food.
Animal studies also have the potential to predict allergenicity in humans,
although scientists have not yet identified an animal that suffers from
allergic reactions the same way that humans do. The brown Norway rat
has provided the closest approximation to human allergic reactions to
several major food allergens. However, animal models—as predictors of
allergenic responses in humans—are not scientifically accepted at this
time.
Biotechnology experts whom we contacted from a consumer group, FDA,
academic institutions, research institutions, the European Union and
biotechnology companies said that the current regimen of tests has been
adequate for assessing the safety of GM foods.13 All but one expert
considered the regimen of tests to be “good” or “very good” for ensuring
the safety of GM foods for public consumption, and the remaining expert
viewed the tests as “fair.” While the experts noted that individual tests
have limitations, most experts agreed that results from the regimen of
tests provide the weight of evidence needed for scientists to make an
accurate assessment of risk. 14
A distinction made by an academician and regulatory officials is that the
available tests do not guarantee absolute safety of GM foods, but
comparable safety. There is no assurance that even conventional foods are
completely safe, since some people suffer from allergic reactions, and
conventional foods can contain toxins and antinutrients. Because they
                                                                                                                                   
13 Some consumer groups, as well as some scientists from the European Union, have
questioned the ethical or cultural appropriateness of genetically modifying foods.
14 According to FDA officials, they are aware of only one example—involving the Brazil
nut—of GM food development where an allergen-producing gene was transferred. In this
case, the regimen of tests used in safety assessments for GM foods successfully identified
the presence of the allergen-producing gene before the product was ever submitted for
FDA review.  The company subsequently discontinued research, development, and testing
of the food.
Animal Studies
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have been consumed for many years, though, conventional foods are used
as the standard for comparison in assessing the safety of GM foods, and
experts note that the available tests are capable of making this
comparison.
While experts agree that the available regimen of tests is adequate for
safety assessments, there are limitations to individual tests. For example,
there are limitations to the acceptability of amino acid sequence similarity
test results, in part because there is not agreement on what level of amino
acid similarity indicates a likelihood of allergenicity and, therefore, the
need for additional testing. Industry scientists assert that as long as amino
acid sequences in a protein are less than 50 percent identical to those in
known allergens, then the protein should not raise concerns. On the other
hand, a scientist associated with a consumer group, as well as a report
from the United Nations’ Food and Agriculture Organization, believe a
more conservative level, such as less than 35 percent identical, is
appropriate. Thus, experts from industry and consumer groups suggest
that reaching agreement on this parameter would increase the consistency
with which these tests are applied.
In vitro digestibility tests also have limitations because they can yield
inaccurate results when performed under inappropriate parameters, such
as improper digestive fluid pH levels. 15 If a GM food protein is tested at a
pH level representative of intestine digestion, yet the protein in real life is
digested at a different pH level in the stomach, then the results of the test
are not valid for reaching conclusions on the GM food’s likely effect in
humans. FDA officials note that there is growing acceptance that the
proper pH level for digestive stability tests is the pH level of the human
stomach. As a result, experts from industry and consumer groups suggest
that reaching agreement on the parameters in digestive stability tests—
such as proper pH ranges—would help ensure that they are performed
properly.
Information on acceptable testing procedures (including parameters) is
available from a variety of sources. For instance, AOAC International16
documents standardized tests and test procedures, such as test procedures
for examining nutrient levels in a GM food. Other groups, such as the
American Oil Chemists’ Society and the American Association of Cereal
                                                                                                                                   
15 The pH level indicates the degree of acidity or alkalinity.
16 This organization was formerly known as the Association of Official Analytical Chemists.
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Chemists also have information on official tests and test procedures.
However, there is no centralized source of information on these
procedures. Although FDA maintains a Web site with guidance for
consultations, the Web site does not contain information about acceptable
testing procedures.
According to FDA, it has the necessary controls to ensure it obtains the
safety data needed for its GM food evaluations. In examining a selection of
submissions, we found that companies adhered to FDA’s recommended
procedures for the type of data to be submitted. However, biotechnology
experts state that the agency’s overall evaluation process could be
enhanced by randomly verifying the test data that companies provide and
by increasing the transparency of the evaluation process—including more
clearly communicating the scientific rationale for the agency’s final
decision on GM food safety assessments. FDA believes that making these
changes would enhance the public’s confidence in the agency’s evaluation
process.
According to agency officials, FDA has several management practices that,
in aggregate, constitute internal controls.17 The officials state that these
practices effectively ensure FDA obtains the data necessary for evaluating
the potential risks of GM foods. These practices include:
• communicating clearly what safety data are important to FDA’s
evaluations of GM food safety,
• having teams of FDA experts representing diverse disciplines perform the
evaluations, and
• tailoring the level of evaluation to match the degree of each GM food’s
novelty.
One key indication of the effectiveness of these practices is FDA’s ability
to determine when data are inadequate and to specify the additional data
important to a complete evaluation. In the cases we examined when the
                                                                                                                                   
17 Standards for Internal Control in the Federal Government (GAO/AIMD-00-21.3.1,
Washington, D. C.: November 1999) defines internal controls as an integral component of
an organization’s management that provides reasonable assurance that effectiveness and
efficiency of operations and compliance with applicable laws and regulations are being
achieved.
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company’s initial submission of data was insufficient, FDA was able to
specify and obtain additional data from the company.
For a GM food, the evaluation process, known as a consultation, generally
lasts between 18 months and 3 years, according to FDA officials. In what
FDA calls the “initial” phase of the consultation, FDA and company
officials discuss what safety data will be needed for a GM food
submission. In the next or “final” phase, the company prepares a detailed
report summarizing this data and submits it to FDA. After receiving and
evaluating the report, FDA officials prepare a “memo to file.” This memo is
the formal document in which FDA summarizes and evaluates everything
the company has submitted. Consultation is complete when FDA
determines that it has no further questions regarding the safety of the GM
food and informs the company of this conclusion in a letter signed by the
director of the FDA’s Office of Food Additive Safety. Receiving such a
letter is generally helpful to companies in marketing their product.
In FDA’s 1992 policy statement and its subsequent 1997 guidance, the
agency clearly states what information companies should submit for FDA
to assess the safety of GM foods. Specifically, the 1992 statement includes
several risk assessment decision trees that provide a step-by-step
approach to testing. FDA recommends that companies follow this
approach in their assessments of GM foods. Using this approach,
companies must show whether any allergens, toxins, or antinutrients have
been introduced or enhanced. FDA’s 1997 guidance builds upon the 1992
policy statement by describing in more detail the process, procedures, and
time frames pertaining to the initial and final consultations.
FDA officials stated that the principles embodied in their 1992 policy
statement guided the consultations for the 50 GM foods evaluated so far
and that companies have closely adhered to these principles. In examining
five submissions,18 we found that companies adhered closely to the 1992
policy statement. For example, a 1996 submission for a GM soybean19
shows step-by-step adherence to the allergenicity decision tree established
                                                                                                                                   
18 The five submissions reviewed are representative of the three main types of GM plants
evaluated as of April 2002: pest-resistant plants, herbicide-tolerant plants, and plants having
modified oils. Specifically, we reviewed submissions for a pest-resistant corn; an herbicide-
tolerant sugar beet and soybean; and high oleic-acid soybean oil and laurate canola oil.
19 This GM soybean was engineered to contain a substantially higher percentage of oleic
acid.
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in the 1992 policy statement. Extensive data submitted by the company
enabled FDA to conclude that it had no unanswered questions about the
safety of the soybean. Later submissions involving an herbicide-tolerant
sugar beet and pest-resistant corn also showed a close adherence to the
1992 policy statement.
Evaluations of GM food safety submissions must include concurrence
from every member of a highly qualified team known as the Biotechnology
Evaluation Team.20 The 1997 guidance states that the evaluation teams
generally will be composed of a consumer safety officer (who serves as
the project manager), molecular biologist, chemist, environmental
scientist, toxicologist, and nutritionist. The guidance also states that the
evaluation teams may be supplemented with additional expertise on a
case-by-case basis. According to agency officials, these experts are
qualified to perform what is effectively a peer review21 of each submission.
Consumer safety officers, who generally have doctorates in relevant
disciplines, including molecular biology, cell biology, or immunology,
chair the teams. According to FDA officials, in addition to their scientific
credentials, the consumer safety officers know what is needed for the
administrative record for each submission. This knowledge encompasses
the laws and regulations, such as the Federal Food, Drug, and Cosmetic
Act, as well as specific pertinent procedures, such as FDA’s 1992 policy
statement. According to FDA officials, the combination of scientific and
administrative expertise makes the consumer safety officers effective
leaders of the teams.
FDA officials indicated that each member of an evaluation team reviews
the entire file for a given GM food submission. These officials viewed this
as another strength of the evaluation process. In particular, they stressed
that the final evaluation is not a “piecemeal” evaluation in which, for
example, the toxicologist receives only the toxicological data to review.
Rather, each team member receives and examines all the data that the
company has submitted. Further, team members must document in writing
the results of all key interactions with a company throughout the course of
                                                                                                                                   
20 Within FDA, the Center for Food Safety and Applied Nutrition oversees the
Biotechnology Evaluation Teams for consultations on human food. FDA’s Center for
Veterinary Medicine oversees teams for consultations involving GM animal feed.
21 Peer review is the critical evaluation of data, analysis, or documents by professional
colleagues. It is the traditional method of quality control in science.
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the evaluation; this documentation is then available for the whole team to
evaluate. Lastly, the entire team must concur with the final draft of the
memo to file, which is usually prepared by the consumer safety officer.
In summary, FDA officials told us that the expertise of the Biotechnology
Evaluation Team members coupled with the multiple reviews of
information enables the team to adequately evaluate safety assessments
and determine if and when more data is needed.
According to agency officials, FDA’s practice of varying its level of
evaluation based on the degree of novelty of the GM food submission
allows it to devote resources where they are most needed, thus assuring
that Biotechnology Evaluation Teams have time to obtain necessary safety
data. FDA’s evaluation of one company’s GM tomato provides an example
of a detailed evaluation of a novel submission that went through both the
initial and final consultations. Specifically, the Biotechnology Evaluation
Team requested extensive detail from the company on the modification of
the tomato, which involved the insertion of one gene to delay ripening and
another gene to show that this trait was transferred. FDA’s documentation
of its evaluation presented background information on these
modifications, a point-by-point evaluation of the company’s food safety
assessment, and FDA’s conclusion that the tomato was not significantly
different from conventional tomatoes.
By contrast, FDA officials stated that evaluations of company submissions
for GM foods similar to GM foods previously evaluated by the agency
(such as a virus-resistant squash and various herbicide-tolerant corns)
required fewer agency resources because these submissions skipped the
initial consultation and proceeded to the final consultation. In fact, FDA’s
1997 guidance states that a company might skip the initial consultation
and go directly to the final consultation by submitting its final report.
According to FDA officials, this skipping often occurs when a company
has made multiple submissions for similar GM foods involving only minor
variations from one case to the next. Having once gone through the full
consultation process for a specific genetic modification, such a company
is familiar with the kinds of safety information that FDA expects and thus
can proceed directly to preparing a final report for similar cases. FDA’s
documentation of its evaluation of such submissions can be less detailed.
According to FDA officials, in cases in which the agency determines that
the data submitted by a company are insufficient, the company has always
cooperated with FDA by performing additional tests and/or submitting the
data needed. FDA officials described three types of situations where they
FDA Tailors Its Evaluation to
Match the Degree of Novelty in
Each Submission
FDA Believes It Obtains
Complete, Consistent Data
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have requested additional data and companies have responded: (1) the
absence of a reliable or “validated” method for performing a test; (2)
reliance on a prevailing scientific “assumption” that, when tested at FDA’s
request, was proven incorrect; and (3) inconsistent or incomplete data in
the final reports.
The first situation involved the lack of a reliable method for testing
tomatine, a naturally occurring toxin in tomatoes. The company that
encountered this problem was inexperienced in analytical chemistry, and
the laboratory with which it was working did not have an acceptable
method. In evaluating the measurements of tomatine submitted by the
company, FDA officials found these data unconvincing. As a result, FDA
officials suggested that the company find a more appropriate method. In
response, the company obtained a suitable method from another
laboratory and later provided FDA with new data that the agency found
convincing.
The second situation is illustrated by FDA’s evaluation of a GM tomato
altered to delay ripening. In this submission, the company assumed that
only a certain segment of DNA was transferred. FDA asked the company
to prove the accuracy of this assumption. Testing by the company then
revealed that additional DNA had been transferred. This discovery led to
more thorough analysis of the genetic modifications, including additional
efforts to ensure that the transfer of extra DNA did not cause unintended
changes.
In the third situation, FDA noted discrepancies in the data in final reports
involving GM cotton, rice, and canola and requested the relevant
companies to correct the information, which they did.
Biotechnology experts state, and FDA agrees, that its overall evaluation
process for assessing the safety of GM foods could be enhanced by
• verifying the GM food-related test data that companies provide, and
• increasing the transparency of the evaluation process.
Biotechnology experts from consumer groups and academia state that
FDA’s evaluation process could be enhanced if the agency validated
companies’ test results on proposed GM products by reviewing raw data
(e.g., the actual, unverified test results). Further, FDA believes that
occasional reviews of the raw data developed by companies would further
enhance the credibility of, and public confidence in, the overall safety data
FDA Evaluations of GM
Foods Could be Enhanced
FDA Could Validate Company
Safety Data
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that companies submit. In addition, we believe occasional data verification
by a federal agency is necessary to (1) identify the risk of the agency’s
receiving faulty data from external sources and (2) ensure that no one
agent is allowed to control every key aspect of a safety assessment.22
FDA officials stated that they do not believe it is necessary for the agency
to routinely review raw data for two reasons. First, the risk of incurring
criminal penalties for deliberately submitting false data to FDA provides a
significant degree of deterrence. Second, FDA’s evaluation process
constitutes a peer review of the safety data that will generally detect any
problems.23 However, these officials added that an occasional review of
raw data, performed on a random basis, would further help ensure the
reliability of FDA’s evaluation of these foods, and thus enhance public
confidence in the agency’s evaluation process.
Officials from a major biotech company described three types of GM food
safety data developed for each submission and available for FDA’s review:
(1) raw data, (2) refinements and comprehensive interpretations of the
raw data, and (3) summaries of these interpretations. According to these
officials, FDA has reviewed the summaries, and in some instances the
comprehensive interpretations, but has not reviewed the raw data. These
officials note, and FDA officials concur, that nothing prevents FDA from
reviewing these raw data. In general, these raw data are readily available
from companies. The company officials also note that EPA has
occasionally reviewed raw data in its safety assessments of GM plants
regarding their environmental effects. Moreover, FDA officials stated the
agency reviews raw data in its safety assessments of new drug
applications.
Experts from consumer groups and academia have stated that the
transparency of the agency’s evaluation process for GM foods could be
enhanced if FDA described more clearly the scientific rationale for its
safety decisions in its memo to file. FDA agrees. Guidelines issued by the
                                                                                                                                   
22 U.S. General Accounting Office, Internal Control Management and Evaluation Tool
GAO-01-1008G (Washington, D.C.: August 2001).
23 Among other factors not directly linked with internal controls, FDA officials pointed out
that the majority of requests for access to GM food submissions through the Freedom of
Information Act come from competitors, who, according to these officials, would likewise
be quick to detect a problem with the data. Scientists, consumer groups, and other
interested parties have also asked for access to these submissions. However, the data
reviewed by these groups does not include the raw data.
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Office of Management and Budget on the quality of information
disseminated by federal agencies state that transparency is important in
reviews of technical information and that these reviews should be
conducted in an open and rigorous manner.24 Yet critics have stated that
FDA’s current memos to file do not adequately communicate the scientific
rationale for the decisions. Some consumer groups have pointed out the
brevity of some of the memos and described them as “perfunctory”
summaries of company data that provide little or no insight into FDA’s
evaluation of the data. Likewise, the Council for Agricultural and Science
Technology, a group of universities and companies established to provide
a more scientific basis for analyzing and prioritizing agricultural issues,
stated that FDA does not adequately clarify in its memos to file the basis
for its decisions on GM food submissions. Our review of memos to file for
the 50 GM food products evaluated by FDA as of April 2002 confirms that
these memos do not clearly explain the scientific rationale for FDA’s
decisions.
In response to these concerns, FDA officials note that the memos to file
had originally been created for FDA’s internal use rather than as public
documents. Thus, they were not designed to provide detailed rationales of
FDA’s decisions on GM food submissions. In addition, FDA officials said
that some memos are brief because they record decisions on GM foods
that are very similar to previously evaluated GM foods. However, FDA
officials acknowledge that FDA could do more to inform the public of the
basis for their decisions. For example, FDA could include comments in the
memos to file that better reflected the context of the evaluation (for
instance, its similarity to previous evaluations), the adequacy of the tests
performed by the company, and the level of evaluation provided by FDA.
For those memos to file on submissions for GM foods that are similar to
GM foods previously evaluated, FDA could make reference to earlier,
similar submissions having a more detailed memo to file.
                                                                                                                                   
24 Guidelines for Ensuring and Maximizing the Quality, Utility, and Integrity of
Information Disseminated by Federal Agencies (Office of Management and Budget,
Washington, D. C.: January 2002).
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Scientists expect future GM foods to include modifications of plant
composition that may enhance the nutritional value of these foods but may
also increase the difficulty of assessing their safety. While current tests
have been adequate for evaluating the small number of relatively simple
compositional changes made so far, some scientists believe that new
testing technologies under development may be needed to assess the
safety of these more complex GM foods. Scientists have diverging views
on the potential role of these new technologies: some view them as a
useful supplement to existing tests, while others view them as a new, more
comprehensive way to assess the safety of all changes in GM foods.
However, the lack of technical standards for these new technologies and
proof of their reliability prevents their current use.
Until now, most genetic modifications of plants have been aimed at
increasing or protecting crop yield. These modifications have generally
focused on the portions of plants, such as cornstalks, that are not
consumed by humans. However, many scientists believe that the current
wave of yield-related modifications will expand to include a new wave of
genetic modifications involving compositional changes in the foods to
enhance their nutritional value. For example, “golden” rice is a GM food
under development that was modified to contain beta-carotene, a
precursor of vitamin A.25 Golden rice may help to reduce the incidence of
blindness in countries where rice is a dietary staple and malnutrition is
common. Also under development are compositional changes that will
increase the levels of vitamin E in foods. Plants are the primary source of
this vitamin, which is believed to have cancer-preventing properties, but
plants generally contain it in relatively low concentrations. A gene
controlling vitamin E production was transferred recently to a member of
the mustard plant family, which subsequently exhibited a nine-fold
increase in this vitamin. According to a recent report,26 incorporation of
this gene into major crops such as soybeans, canola, and corn is probably
not far in the future.
In addition to increasing nutrients in GM foods, scientists are working to
reduce the presence of allergens, toxins, and antinutrients. For example,
                                                                                                                                   
25 The human body converts beta-carotene into vitamin A if the body is deficient in
vitamin A.
26 Pew Initiative on Food and Biotechnology, Harvest on the Horizon: Future Uses of
Agricultural Biotechnology, Washington, D. C., September 2001.
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scientists have genetically modified wheat, one of the major allergenic
foods, to stimulate a gene that diminishes wheat’s allergenic properties.
Scientists are also seeking ways to reduce toxic substances, such as
alkaloids in potatoes, by inserting genes that block their production.
Preliminary findings have indicated that GM potatoes produced fewer of
these alkaloids. Likewise, some plants, especially cereals and legumes, are
nutritious foods but contain varying amounts of antinutrients. Genetic
modifications are being explored to reduce these antinutrients.
If adopted, FDA’s proposed rulemaking mandating the testing of all GM
foods prior to commercialization will represent a timely response to this
new wave of GM foods. For example, the preamble to the rule notes that
some of the new ingredients in GM foods will significantly differ from
ingredients that have a history of safe use. The rule also notes that
products derived from this advanced biotechnology will present more
complex safety and regulatory issues than those seen to date. The
proposed rule concludes that nontraditional strategies for evaluating food
safety will become the norm as the use of biotechnology expands. FDA
officials explained that “nontraditional strategies” could include new
technologies under development such as those described in the next
section.
Some scientists believe that testing technologies being developed but not
yet widely applied to GM foods may be useful in assessing the safety of
compositional changes and detecting unintended effects.27 In contrast to
current tests that examine the human health effects of transferred genes
and other relevant components on a highly selective basis, the new
technologies will examine essentially all of the components—such as
DNA, proteins, and metabolites28—in conventional and GM plants
simultaneously to detect any differences. These new technologies include
                                                                                                                                   
27 Unintended effects involve the accidental creation of an allergen, enhancement of a toxin
or antinutrient, or unintentional alteration of the nutritional profile of a food. Unintended
effects can also involve changes in crop yield and growth rates.
28 Metabolites are small molecules in living cells. These small molecules include vitamins
(with potential benefits for human health) and alkaloids (a major source of toxicity in
plants). Their “smallness” is defined in contrast to generally much larger molecules such as
proteins.
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• gene chips that use thousands of droplets of DNA on glass chips to
identify gene sequences and determine the expression level or abundance
of the genes;
• proteomics which can analyze up to 100,000 proteins simultaneously; and
• metabolic profiling that can analyze the 2,000 to 3,000 metabolites in
people and 3,000 to 5,000 metabolites in plants.
In essence, these new technologies combine huge increases in automated
computing power with traditional testing technologies to identify
differences between conventional and GM foods in ways that would have
been impossible even a few years ago.
A university scientist further explained the contrast between the current
and new technologies by noting that traditional tests focus on known
toxins and nutrients in a “targeted” approach, whereas new technologies
use a “non-targeted” approach to increase the chance of detecting
unintended effects of genetic modifications such as the creation of a toxin.
According to this scientist, the latter approach has particular applicability
to second-generation plants with extensive modifications, which may be
more likely to have unintended effects. For example, a scientist with a
consumer group stated that the new technologies may be useful in
detecting unintended effects that traditional tests, such as those for
digestibility, are not likely to identify. Other scientists expressed the need
for caution and additional information to determine the potential role of
these new technologies.
Gene chips consist of grids of thousands of droplets of DNA on small glass
surfaces. The chip-based DNA can bind with the DNA or RNA being tested
to determine which genes are present or are being activated. Used in
conjunction with DNA and RNA databases under development at various
universities and other research institutions, this testing technique has
yielded insights into areas such as the ripening process of tomatoes and its
relation to toxins and nutrients. The major advantage of gene chips over
conventional testing techniques is that they allow small-scale analysis of
thousands of genes at the same time in a precise and quantitative manner.
According to a university scientist, researchers are determining the extent
to which this technology may be effective in assessing GM food safety.
Proteomics is a biotechnology technique used to identify many proteins
simultaneously in a given organism. Using chemical analyses and
computers, proteomics goes beyond plant studies focusing on DNA and
RNA, which do not provide information on the actual creation of the
proteins. Proteomics has been introduced successfully in medical
Gene Chips
Proteomics
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disciplines such as oncology, where it has helped to identify proteins
associated with cancer, but it has not yet been used to evaluate the safety
of GM foods for two reasons. First, there are a large number of proteins
that need to be analyzed in any given plant. Second, the function of
proteins in a plant may change depending on their interaction with
different cells and tissues. According to a university scientist, researchers
are working to expedite the analysis of proteins in plants.
Metabolic profiling uses chemical analyses and computers to obtain a
simultaneous, detailed look at all of the small molecules (metabolites) in a
given GM plant to determine the extent to which these molecules have
changed in comparison to a conventional plant, if at all. According to
scientists at one company involved in developing metabolic profiling, this
technique can determine whether a specific, intended change in a small
molecule has been achieved. It can also identify any unintended changes
in other small molecules—changes such as increased alkaloids, which are
a major source of toxicity in plants. If the profiling finds no unintended
changes in these molecules, then it offers a reasonable certainty that the
genetic modification has not led to any changes with potentially adverse
health consequences. In general, metabolic profiling has not yet been used
commercially. However, scientists working with this technique believe
that it may play a potentially important role as a safety screening tool for
companies developing complex, compositionally altered GM foods in the
future. In addition, scientists state that it shows promise in the health care
field in assessing the safety of future new drugs.
Despite progress in developing and applying gene chips, proteomics, and
metabolic profiling, technical limitations currently prevent their use to
assess the safety of GM foods. Biotechnology experts told us that internal
standards must be developed for the methods and chemicals used in these
new technologies and that the reliability of these technologies must be
proven. For example, in gene chip testing, experts state that
standardization of the thousands of genes represented on the chips is
essential to improve the quality of this technology. Further, experts state
that the chemical analysis used in proteomics needs to be enhanced to
improve its reliability.
Beyond these technical challenges, however, lies a more fundamental
problem. Because these new technologies are more sensitive, they may
identify a flood of differences between conventional and GM food
products that existing tests could not detect. Not all of these differences
will stem from genetic modification. Some of the differences will stem
Metabolic Profiling
Challenges to Adopting
New Testing Technologies
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from the tremendous natural variations in all plants caused by factors such
as the maturity of the plants and a wide range of environmental
conditions, such as temperature, moisture, amount of daylight, and unique
soil conditions that vary by region of the country. For example, there can
be a tenfold difference in the level of key compositional elements, such as
nutrients, depending on the region in which soybeans are grown. Thus,
according to a biotechnology company expert, it will be difficult to
differentiate naturally occurring changes from the effects of deliberate
genetic modifications.
Industry and university scientists have expressed strong concerns about
the problem of interpreting the potential significance of these differences.
They believe that the new technologies will be of limited value unless
baseline data on the natural variations of nutrients and other
compositional values for each of the major food crops can be developed.
However, experts disagree on the difficulty of developing this baseline.
Some experts, including those at FDA, assert that developing the baseline
will be difficult because of the extreme sensitivity of plants to
environmental variations. Other experts, especially those pioneering the
new techniques, state that a baseline can definitely be established in the
next few years.
Some companies have started to respond to the need for baseline
information. New developments in technology have begun to provide an
encyclopedic database on natural variations in plants and on the variations
resulting from deliberate genetic modification. For example, using
metabolic profiling, one company has analyzed approximately 150
characteristics, such as the size and rate of growth, of individual plants.
The company has also examined about 12,000 genes in one species of
plant—a member of the mustard family—and analyzed the consequences
of eliminating or stimulating particular genes. About one million mustard
plants of this type have been analyzed in this line of research. Even with
the development of baseline data and the detection of differences,
scientists will still need to evaluate the significance of these differences
for human health. Appendix II provides more information regarding
advancements in the development of baseline information and the
experimental use of metabolic profiling to assess the safety of GM foods.
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Scientists and federal regulatory officials we contacted generally agreed
that long-term monitoring of the human health risks of GM foods through
epidemiological studies29 is not necessary because there is no scientific
evidence suggesting any long-term harm from these foods. These scientists
and officials also stated that it would be very difficult, if not impossible, to
develop a process for monitoring the long-term health risks of GM foods
because of the technical challenges in developing such a system. A recent
report by the United Nations also expresses skepticism about the
feasibility of identifying long-term health effects from GM foods.
The scientists and federal regulatory officials generally agreed that
because there is no scientific evidence that GM foods cause long-term
harm, such as increased cancer rates, there is no plausible hypothesis of
harm. Researchers need such a hypothesis in order to know what problem
to search for, test, and potentially measure. For example, in the
Framingham Heart Study of Massachusetts, researchers hypothesized that
there were biological and environmental factors that contributed to
cardiovascular disease. Using this hypothesis, researchers were able to
design a study that established a relationship between the levels of
cholesterol and the risk of heart disease. The resulting effort, comprising
more than 10,000 participants over two generations (more than 50 years),
developed groundbreaking information on the major risk factors
associated with heart disease, stroke, and other diseases. For example,
researchers found that a lifestyle typified by a faulty diet, sedentary living,
or unrestrained weight gain exacerbated disease risk factors and
influenced the occurrence of cardiovascular problems.
Without a plausible hypothesis such as that used in the Framingham study,
most scientists we contacted said that epidemiological studies on GM
foods would not provide any useful information. Two of these scientists
also noted that the primary ways in which foods might cause long-term
harm are through (1) proteins that remain stable during human digestion,
thereby retaining the potential to exert adverse effects such as a toxic
reaction, and (2) detrimental changes in nutrients and other food
components. However, for all 50 GM food plants reviewed by FDA as of
April 2002, the genetically modified proteins in those foods that potentially
                                                                                                                                   
29 Epidemiological studies assess various factors influencing the occurrence, distribution,
prevention, and control of disease, injury, and other health-related events in a defined
human population. These studies often run for 20 years or more, involve thousands of
people, and cost millions of dollars.
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could be cause for concern have been shown in tests to be rapidly
digested. Further, the two GM food plants reviewed that produced
modified oils—soybean and canola—had nutritional profiles that were
similar to or better than their conventional counterparts. As discussed
previously, the soybean oil was modified to be more nutritious than
conventional soybean oil. The canola oil was modified to contain a higher
level of laurate, which would allow it to substitute for imported tropical
oils, such as palm kernel oil. However, industry determined that the total
intake of laurate in the diet would not change significantly by substituting
the improved canola oil for the tropical oil. Accordingly, industry officials
stated, and FDA officials concurred, that long-term studies of health
effects of this oil would not be needed.
Scientists and federal regulatory officials also stated that there are
substantial technical challenges that make long-term monitoring of the
health effects of GM foods virtually impossible. The challenges cited
include the following:
• Conducting long-term monitoring would require both an experimental
group that has consumed GM foods and a control group. The control
group would consist of people who could confirm that they do not eat GM
foods. In countries such as the United States, where labeling is not
required for GM foods, reliably identifying such control groups would be
virtually impossible.
• Even if GM foods were labeled in the United States, it would be very
difficult to separate the health effects of GM foods from those of their
conventional counterparts, since to date there has been very little
nutritional difference between these foods. Further, over long periods of
time, there would be practical challenges in feeding both the experimental
and controls groups diets comprising large amounts of GM food, such as
soybeans or corn, and their conventional counterparts.
• Since the long-term human health effects of consuming most foods are not
well understood, there is no baseline information against which to assess
health effects caused by GM foods.
• Changes in human food consumption patterns, specifically the addition
and removal of various foods, add new variables to the diet and compound
the difficulty of conducting long-term monitoring. The fairly recent
introduction of the kiwi fruit (to which some individuals are allergic) and
the reduction of the use of cotton seed (to which some individuals have
also been allergic) as a protein source in candy or breads illustrate the
challenges in monitoring food consumption patterns when conducting a
Technical Challenges Make
Long-Term Monitoring
Infeasible
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20-to-30 year epidemiological study.
A report issued in June 2000 by the United Nations’ Food and Agriculture
Organization and World Health Organization supports the scientists’ and
regulators’ views about the infeasibility of identifying long-term health
effects from GM foods.30 The report states that, in general, very little is
known about the potential long-term effects of any foods, and that
identification of such effects is further confounded by the great variability
in the way people react to foods.31 The report also states that
epidemiological studies are not likely to differentiate the health effects of
GM foods from the many undesirable effects of conventional foods, which
according to scientists include the effects of consuming cholesterol and
fats. Accordingly, the report concludes that the identification of long-term
effects specifically attributable to GM foods is highly unlikely.
Given the challenges to long-term monitoring, federal regulatory officials,
as well as some U.S. and European scientists, state that the best defense
against long-term health risks from GM foods is an effective pre-market
safety assessment process.
Biotechnology experts believe that the current regimen of tests has been
adequate for ensuring that GM foods marketed to consumers are as safe as
conventional foods. However, some of these experts also believe that the
agency’s evaluation process could be enhanced. Specifically, FDA could
verify companies’ summary test data on GM foods, thus further ensuring
the accuracy and completeness of this data. In addition, the agency could
more clearly explain to the public the scientific rationale for its evaluation
of these foods’ safety, thereby increasing the transparency of, and public
confidence in, FDA’s evaluation process. By addressing these issues,
FDA’s assurance to consumers that GM foods are safe could be
strengthened.
To enhance FDA’s safety evaluations of GM foods, we recommend that the
Deputy Commissioner of Food and Drugs direct the agency’s Center for
Food Safety and Applied Nutrition to
                                                                                                                                   
30 FAO/WHO (2000b) Safety Aspects of Genetically Modified Foods of Plant Origin. Report
of a Joint FAO/WHO Expert Consultation on Foods Derived from Biotechnology (Geneva,
Switzerland, May 29 –June 2, 2000).
31 According to scientists we contacted, this especially includes foods containing allergens.
Conclusions
Recommendations for
Executive Action
Page 33 GAO-02-566  Genetically Modified Foods
• obtain, on a random basis, raw test data from companies, during or after
consultations, as a means of verifying the completeness and accuracy of
the summary test data submitted by companies; and
• expand its memos to file recording its decisions about GM foods to
provide greater detail about its evaluations of the foods, including the level
of evaluation provided, the similarity of the foods to foods previously
evaluated, and the adequacy of the tests performed by the submitting
companies.
We provided FDA with a draft of this report for review and comment. In its
written comments, FDA stated it believes that its current process for
evaluating bioengineered foods provides appropriate oversight but agreed
that enhancements can be made. Specifically, concerning the need to
randomly review raw safety data, FDA agreed that occasional audits
would provide additional assurance to the public that pre-market
decisions about bioengineered foods are based on sound science and that
safety and regulatory issues are resolved prior to commercial distribution.
Concerning the expansion of its memos to file, the agency agreed that
providing greater detail on its decisions about the safety of GM foods
would enhance public understanding and confidence in the evaluation
process. The agency noted that actions in its proposed rule—titled
Premarket Notice Concerning Bioengineered Foods (66 FR 4706, January
18, 2001)—are relevant to our recommendations. FDA explicitly states it
will evaluate whether to adopt occasional audits as it evaluates comments
on its proposed rule. Since FDA officials told us that some of its proposed
rule changes in the Federal Register have taken years to implement, we
believe that the public’s interests would be served by implementing our
recommendations separately from the proposed rule approval process.
FDA also had general comments about the terms and definitions used in
discussing agricultural biotechnology. FDA stated that our draft report
avoided many of the pitfalls in terminology and in general was written in a
manner that will be understandable to the public. However, the agency
believes the use of terms such as “Genetically Modified Food” in the title
and “GM food” in the text can be misleading and such foods are more
commonly referred to as bioengineered foods. While perhaps the scientific
community refers to these foods as bioengineered, the lay public is more
familiar with the term genetically modified foods. Accordingly, we have
continued to use the term genetically modified, which is defined on page
one of our report.
Agency Comments
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Separately from its written comments, FDA provided us with some
technical changes, which we incorporated into the report where
appropriate. FDA’s written comments are presented in appendix III.
We performed our review from July 2001 through May 2002 in accordance
with generally accepted government auditing standards. (See app. I for our
objectives, scope, and methodology.)
We are sending copies of this report to congressional committees with
jurisdiction over food safety programs, the Deputy Commissioner of Food
and Drugs, the Director, Office of Management and Budget, and other
interested parties. We will also make copies available to others upon
request.  In addition, the report will be available at no charge on the GAO
Web site at http://www.gao.gov.
If you or your staff have any questions about this report, please call me at
(202) 512-3841. Key contributors to this report are listed in appendix IV.
Lawrence J. Dyckman
Director, Natural Resources and Environment
Appendix I: Objectives, Scope, and
Methodology
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Representatives John Baldacci and John Tierney asked us to (1) identify
the types of potential human health risks associated with genetically
modified (GM) foods and experts’ views on the adequacy of tests used to
evaluate these risks, (2) describe the Food and Drug Administration’s
(FDA) controls for ensuring that companies submit test data it requests
and identify experts’ views on the agency’s overall evaluations of these
foods, (3) describe potential changes in future GM foods and any
associated changes needed in tests to evaluate them, and (4) identify
experts’ views on the necessity and feasibility of monitoring the long-term
health risks of these foods.
In addressing our review objectives, we interviewed representatives from
U.S. consumer groups, academic and research institutions, federal
regulatory agencies, and the biotechnology industry. We also E-mailed a
set of questions to experts representing a variety of positions on
biotechnology issues. We selected these experts in consultation with
officials from the National Academy of Science’s National Research
Council. These experts included scientists from the Center for Science in
the Public Interest, the Union of Concerned Scientists, the Biotechnology
Center of the University of Illinois, the Health Sciences Center of Tulane
University, FDA, the Aventis Corp., the DuPont Corp., the Monsanto Corp.,
and Paradigm Genetics, Inc. In addition, we analyzed reports, policy
documents, or issue papers from the Center for Science in the Public
Interest, the Consumer Federation of America, the Union of Concerned
Scientists, the Council for Agricultural Science and Technology, the
National Academy of Sciences, the Pew Initiative on Biotechnology, the
Environmental Protection Agency, FDA, the Biotechnology Industry
Organization, the Institute of Food Technologists, the Codex
Alimentarius,1 and the National Institute for Quality Control of Agricultural
Products at the Wageningen University and Research Center of the
Netherlands. We did not assess the potential environmental risks
associated with GM food production. In addition, since there have been no
GM animals evaluated for commercialization, we did not assess the
potential environmental or human health risks associated with them.
To identify the types of potential health risks of GM foods, we analyzed
and synthesized information from the interviews, E-mail question
responses, and documents regarding these risks. To identify tests
                                                                                                                                   
1 Codex Alimentarius is the joint food standards program for the United Nations’ Food and
Agriculture Organization and the World Health Organization that was established in 1962.
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commonly used by industry to assess GM food safety, we examined
several FDA evaluations of GM food. In examining these evaluations, we
also analyzed how FDA addresses any potential limitations in these tests
and what guidance FDA provides to industry regarding scientifically
acceptable tests. In our E-mail questions, we also asked the experts to
describe any limitations to these tests, and then analyzed and synthesized
their responses, particularly regarding test-specific limitations and
suggestions for improving the tests. In addition, we asked whether there
were any limitations to FDA’s guidance on acceptable tests. We then
synthesized their responses, including suggestions for improving FDA’s
guidance.
To describe FDA internal controls for ensuring that companies submit
safety test data requested by the agency, we interviewed FDA officials and
reviewed agency documents about the functions of these internal controls,
specifically (1) FDA’s 1992 Policy on Foods Derived from New Plant
Varieties and its 1997 Guidance on Consultation Procedures that
describe what safety data companies should submit; (2) the qualifications
and roles of the FDA Biotechnology Evaluation Teams responsible for
evaluating these submissions; and (3) FDA’s practice of matching its level
of evaluation to the degree of novelty of the GM food submitted. Further,
we compared the safety data specified in FDA’s 1992 policy with data
provided by companies in five GM food submissions and analyzed the
extent of the companies’ adherence to FDA’s recommended procedures
for safety assessments.2  We contacted officials at the Department of
Health and Human Services’ Office of Inspector General to determine if
they had reviewed FDA’s internal controls. (They had not.) We did not,
however, independently verify the adequacy of FDA’s internal controls. To
identify experts’ views on the agency’s overall evaluations of GM foods, we
interviewed consumer groups, industry officials, and other experts,
analyzed their views and concerns—including any suggestions for
improving FDA’s evaluation process—and reviewed related literature. For
each concern identified with the process, we obtained FDA’s response and
then determined the extent to which FDA’s response effectively addressed
the concern or suggested a need for additional action by FDA. Further, we
examined Office of Management and Budget and GAO guidance and
policies relevant to these concerns.
                                                                                                                                   
2 The five submissions reviewed are representative of the three main types of GM plants
evaluated as of April 2002: pest-resistant plants, herbicide-tolerant plants, and plants having
modified oils.
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To describe the potential changes in future GM foods and associated
changes needed in the tests to evaluate them, we interviewed scientists
and regulators on the likely changes in GM foods and new testing
approaches under development. We also focused several of our E-mail
questions on this topic and analyzed the responses. In addition to E-mail
respondents, we contacted experts from biotechnology companies
concerning research on new, more complex GM foods as well as new
testing approaches that may supplement or replace existing tests. We
synthesized these respondents’ and experts’ views on likely changes to GM
food and the value and challenges of using these new testing approaches.
Further, we reviewed the relevant scientific literature for discussions of
anticipated changes in GM foods and information on specific tests under
development. We also met with scientists developing one of these new
testing approaches to understand its potential value for assessing GM food
safety.
To identify the views of experts on the necessity and feasibility of
monitoring the long-term health risks of GM foods, we asked respondents
to our E-mail questions for an assessment of whether such an effort is
necessary or feasible and then analyzed their responses. Further, we
reviewed a variety of documents concerning the necessity and feasibility
of long-term monitoring, including a recent joint United Nations’ Food and
Agriculture Organization and World Health Organization report, as well as
a recent report by the National Institute for Quality Control of Agricultural
Products at the Wageningen University and Research Center of the
Netherlands. We also discussed the topic with other regulatory officials
connected with monitoring food safety. In particular, we discussed
whether the long-term effects of GM foods could be separated from other
factors that may influence human health.
Finally, we submitted a draft of this report for technical review by
scientists from industry, academia, and a consumer group, and we
incorporated their comments as appropriate.
We conducted our review from July 2001 through May 2002 in accordance
with generally accepted government auditing standards.
Appendix II: Potential Use of Metabolic
Profiling to Compare a GM Plant to Its
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Metabolic profiling could be used as a safety-screening tool for GM foods.
Specifically, as shown in figure 3, special software has allowed one
company to graph the metabolic profile of one variety of mustard plants
and analyze the effects of genetic modifications. In the figure, the vertical
axis in each graph provides a list of different small molecules, or
metabolites, in mustard plants from this variety. The horizontal axis
measures variation or deviation from the metabolite levels in this
conventional variety. The vertical line in the middle of each graph
represents the average value for a range of small molecules, or
metabolites, in this conventional variety. In this example, the company
analyzed thousands of conventional plants from this variety to come up
with a range of naturally occurring metabolite levels. The company then
used the averages of these ranges to generate the vertical line in the
middle of the graphs. The points plotted with squares represent the levels
of small molecules in GM mustard plants. Points appearing to the right of
the center vertical line indicate increased levels of specific small
molecules, while points appearing to the left indicate decreased levels.
The graphs in figure 3 illustrate three scenarios: graph (a) shows a GM
mustard plant with small molecule levels nearly identical to its
conventional counterpart; graph (b) shows a GM mustard plant with a few
easily measurable decreases; and graph (c) represents a GM mustard plant
with many significant differences from the small molecule levels of its
conventional counterpart.
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Figure 3: Metabolic Profiling of Three GM Mustard Plant Varieties in Comparison
with Baseline Data from Their Conventional Counterparts
Note:
Standard deviation is a measure of the probability that an observed value will be different from the
average value.
Graph (a)
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Graph (b)
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Source: Paradigm Genetics, Inc.
If baseline data on normal ranges of variation, such as those developed for
the mustard plants, can be made available for all GM food crops,
companies might use this type of testing to develop safety data. For
example, in graph (a), the absence of significant changes in the small
molecules would strongly indicate that no significant changes had resulted
from the genetic modification. Hence, a change in the risk of allergenicity,
toxicity, or antinutrients would be very unlikely. In the case represented
by graph (b), the software could determine which small molecules have
changed. Then, traditional testing techniques such as toxicity testing,
could be used to determine if the altered small molecules would have any
Graph (c)
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effect on human health, plant growth, or crop yield. In the case shown in
graph (c), scientists would probably not proceed with development and
commercialization of the GM food in the absence of extensive evaluations
for allergens, toxins, or antinutrients, due to the significant differences in
small molecules between it and its conventional counterpart.
Appendix III: Comments from the Department
of Health and Human Services
Page 43 GAO-02-566  Genetically Modified Foods
Appendix III: C mme ts from the
Department of Health and Human Services
Appendix III: Comments from the Department
of Health and Human Services
Page 44 GAO-02-566  Genetically Modified Foods
Appendix III: Comments from the Department
of Health and Human Services
Page 45 GAO-02-566  Genetically Modified Foods
Appendix IV: GAO Contacts and Staff
Acknowledgments
Page 46 GAO-02-566  Genetically Modified Foods
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report.
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